Search results
Could third-party candidate RFK Jr. make a splash in battleground state North Carolina?
Star News via Yahoo News· 22 hours ago“However, the Trump lead over Biden has been reduced to 2 percent – inside the confidence interval of the poll. Joe Biden has improved his poll numbers ...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 3 days agoThese safety results are in keeping with the known toxicities of Enhertu and Perjeta....
Exploring high-quality microbial genomes by assembling short-reads with long-range connectivity -...
Nature· 6 days agoHere, the authors develop Pangaea, an assembler that uses short-reads with long-range connectivity to create high-quality microbial genomes affordably, showing it outperforms existing methods ...
ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?
Pharmaceutical Technology via Yahoo Finance· 2 days agoIn ACE-Breast-02, ARX788 managed to prolong progression-free survival (PFS) compared to LC, with...
Hypertension, albuminuria risks are no worse for kidney donors than for non-donors: Study
Medical Xpress· 6 days agoLiving kidney donors and non-donors have similar risks for hypertension and albuminuria, according...
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following...
Digital Journal· 3 days agoMedicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, presented updated clinical ...
Aphakic Kids' Secondary Lens Implants Pose Risks
Medscape· 3 days agoImplantation of a secondary intraocular lens in children with aphakic eye was associated with complications, refractive errors, and suboptimal visual...
Placing COVID patients in skilled nursing facilities led to increased cases, deaths, study finds
Center for Infectious Disease Research and Policy· 1 day agoOutcomes were assessed during a 15-week follow-up period. The authors found that exposed SNFs had a...
ASCO 24: Data shows survival benefit with J&J’s subcutaneous Rybrevant
Clinical Trials Arena via Yahoo Finance· 5 days agoAdditionally, the median PFS benefit of the SC formulation, was 6.1 months vs 4.3 months (hazard...
First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related...
Forrest City Times-Herald· 5 days agoJohnson & Johnson announced today first data from the Phase 3 PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in patients with locally advanced or metastatic ...